Morgan Stanley Reaffirms “Overweight” Rating for Silence Therapeutics (NASDAQ:SLN)

Morgan Stanley reaffirmed their overweight rating on shares of Silence Therapeutics (NASDAQ:SLN) in a research report sent to investors on Monday, Benzinga reports. The brokerage currently has a $45.00 price objective on the stock.

SLN has been the subject of several other research reports. HC Wainwright restated a buy rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research report on Friday, March 15th. BMO Capital Markets initiated coverage on shares of Silence Therapeutics in a report on Wednesday, January 31st. They issued an outperform rating and a $67.00 price target for the company. Finally, Chardan Capital upped their price objective on Silence Therapeutics from $26.00 to $42.00 and gave the stock a buy rating in a report on Thursday, March 14th.

Silence Therapeutics Price Performance

NASDAQ:SLN opened at $22.27 on Monday. The firm has a market cap of $666.54 million, a PE ratio of -15.25 and a beta of 1.41. The company’s 50-day moving average price is $23.03 and its two-hundred day moving average price is $17.38. The company has a quick ratio of 4.56, a current ratio of 4.56 and a debt-to-equity ratio of 0.01. Silence Therapeutics has a 12 month low of $4.55 and a 12 month high of $27.72.

Silence Therapeutics (NASDAQ:SLN) last released its quarterly earnings results on Wednesday, March 13th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.22). Silence Therapeutics had a negative return on equity of 262.17% and a negative net margin of 171.41%. The business had revenue of $2.61 million for the quarter, compared to the consensus estimate of $11.46 million. On average, equities analysts anticipate that Silence Therapeutics will post -1.38 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vivo Capital LLC increased its position in shares of Silence Therapeutics by 116.7% during the first quarter. Vivo Capital LLC now owns 1,105,454 shares of the company’s stock worth $23,878,000 after buying an additional 595,250 shares during the period. Lynx1 Capital Management LP bought a new position in shares of Silence Therapeutics in the 3rd quarter worth about $2,315,000. Parkman Healthcare Partners LLC lifted its stake in shares of Silence Therapeutics by 20.8% in the 4th quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock valued at $4,046,000 after purchasing an additional 40,063 shares during the period. Finally, SG Americas Securities LLC bought a new stake in shares of Silence Therapeutics during the 4th quarter valued at about $110,000. 98.73% of the stock is owned by institutional investors and hedge funds.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.